SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts
COHR 198.50+0.5%Dec 11 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Logain Ablar who wrote (12057)10/3/2021 5:25:51 PM
From: Sun Tzu  Read Replies (1) of 26766
 
This is not true. With drugs, patents are per application. If your drug is patented for migraine, but later you show that it can also help with anxiety disorder, then you get a 2nd patent starting when the new application is approved. What's more, you get a leg up b/c the safety and side effects of the drug are already known.

>> Asking a pharma company to do a phase II / III trial for a drug like Ivermectin, that is off patent and is inexpensive to manufacture and distribute is problematic.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News